Fairvalue-Calculator Fairvalue-Calculator
EN DE

AmeriCann, Inc (ACAN) Fair Value & Analysis

Real Estate · US · Market cap $2.4K

Price$0.0002
Fair Value$0.0002
Upside+0.0%
Quality92/100
Evidence: Low Range $0.0002 – $0.0002

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AmeriCann, Inc (ACAN) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 92/100 (high quality), in the Real Estate sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

AmeriCann, Inc. designs, develops, leases, and operates cannabis cultivation, processing, and manufacturing facilities in the United States. The company's flagship project is the Massachusetts Cannabis Center that is developed on a 52.6 -acre parcel of undeveloped land located in Freetown, Massachusetts. It also provides medical cannabis and adult-use cannabis. The company was formerly known as Nevada Health Scan, Inc. and changed its name to AmeriCann, Inc. in 2014. The company was incorporated in 2010 and is headquartered in Denver, Colorado.

Open the full interactive analysis →

Similar stocks

Vingroup Joint Stock Company (VIC) -89% CBRE Group (CBRE) -40% Plaza S.A (MALLPLAZA) +55% SAGAB (SAGAB) +18% SAGAA (SAGAA) -26% SAGAD (SAGAD) -20%

Frequently asked questions

Is AmeriCann, Inc (ACAN) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0002 versus a price of $0.0002 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ACAN?
Our 21-model fair value for AmeriCann, Inc is $0.0002 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0002.
What is the quality score of ACAN?
AmeriCann, Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.